ArticleCancer immunology, immunotherapy : CII2007

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.

Martin Sebastian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.